BiotechTube

IBI306 + IBI306

Phase 2/3Completed
0 views this week 0 watching💤 Quiet
Interest: 38/100
38
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Homozygous Familial Hypercholesterolemia

Conditions

Homozygous Familial Hypercholesterolemia

Trial Timeline

Sep 29, 2019 → Dec 30, 2021

NCT ID
NCT04031742

About IBI306 + IBI306

IBI306 + IBI306 is a phase 2/3 stage product being developed by Innovent Biologics for Homozygous Familial Hypercholesterolemia. The current trial status is completed. This product is registered under clinical trial identifier NCT04031742. Target conditions include Homozygous Familial Hypercholesterolemia.

What happened to similar drugs?

1 of 17 similar drugs in Homozygous Familial Hypercholesterolemia were approved

Approved (1) Terminated (0) Active (16)
✅evolocumabAmgenApproved
🔄Rosuvastatin 20mg + PlaceboAstraZenecaPhase 3
🔄Rosuvastatin 20mgAstraZenecaPhase 3
🔄Inclisiran + PlaceboNovartisPhase 3
🔄Inclisiran Sodium for injection + Placebo + PlacebosNovartisPhase 3
🔄InclisiranNovartisPhase 3
🔄Inclisiran + PlaceboNovartisPhase 3

Hype Score Breakdown

Clinical
15
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04031742Phase 2/3Completed

Competing Products

20 competing products in Homozygous Familial Hypercholesterolemia

See all competitors
ProductCompanyStageHype Score
Rosuvastatin 20mg + PlaceboAstraZenecaPhase 3
40
Rosuvastatin 20mgAstraZenecaPhase 3
40
Inclisiran + PlaceboNovartisPhase 3
40
Inclisiran Sodium for injection + Placebo + PlacebosNovartisPhase 3
40
InclisiranNovartisPhase 3
44
INC280 + BuparlisibNovartisPhase 1/2
24
Inclisiran + PlaceboNovartisPhase 3
47
Evolocumab + PlaceboAmgenPhase 2/3
38
evolocumabAmgenApproved
43
MBX-8025 50 mg (Dose Escalation Period 1) + MBX-8025 50 mg or 100 mg (Dose Escalation Period 2) + MBX-8025 50 mg, 100 mg or 200 mg (Dose Escalation Period 3)Gilead SciencesPhase 2
35
BMS-986504 + [14C]-BMS-986504Bristol Myers SquibbPhase 1
36
Lumacaftor Plus Ivacaftor Combination + Ivacaftor + PlaceboVertex PharmaceuticalsPhase 3
40
Placebo + Lumacaftor Plus Ivacaftor Combination + IvacaftorVertex PharmaceuticalsPhase 3
40
Lumacaftor Plus Ivacaftor Combination + IvacaftorVertex PharmaceuticalsPhase 3
40
Alirocumab + PlaceboSanofiPhase 3
40
AK102 + Statins + EzetimibeAkesoPhase 2
35
EvinacumabRegeneron PharmaceuticalsPhase 3
40
evinacumabRegeneron PharmaceuticalsPhase 3
40
REGN1500 250 mg SC/15 mg/kg IV/450 mg SCRegeneron PharmaceuticalsPhase 2
35
EvinacumabRegeneron PharmaceuticalsPre-clinical
26